Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study

Prior treatment

• CASE TISSUE:
  • Patient has von Hippel-Lindau disease (VHL), Hereditary leiomyomatosis and renal cell cancer (HLRCC), Hereditary papillary renal carcinoma (HPRC), or Birt-Hogg-Dube syndrome (BHD)
  • The current target pathology is a recurrence
  • Patient has undergone any prior radiation therapy to target lesion prior to surgery
  • Patient has received chemotherapy class drugs in the 5 years prior to surgery
  • Patient has had any transplants prior to surgery
  • Patient has confirmation of Lynch Syndrome, is presumed to have Lynch Syndrome, or has familial cancer syndrome X
  • Patient has Nephritis (Glomerulus or Interstitial), Poly Cystic Kidney Disease, Glomerulonephropathies or Acquired Renal Kidney Disease
• RENAL CONTROL TISSUE:
  • Patient has von Hippel-Lindau disease (VHL), Hereditary leiomyomatosis and renal cell cancer (HLRCC), Hereditary papillary renal carcinoma (HPRC), or Birt-Hogg-Dube syndrome (BHD).
  • Patient has inflammation, atypia, or hyperplasia of the parenchyma
  • Patient has a current or past history of renal cancer.
  • Patient has undergone any prior radiation therapy to target lesion prior to surgery
  • Patient has received chemotherapy class drugs in the 5 years prior to surgery
  • Patient has had any transplants prior to surgery
  • Patient has confirmation of Lynch Syndrome, is presumed to have Lynch Syndrome, or has familial cancer syndrome X
  • Patient has Nephritis (Glomerulus or Interstitial), Poly Cystic Kidney Disease, Glomerulonephropathies or Acquired Renal Kidney Disease
• UROTHELIAL CONTROL TISSUE:
  • Patient has von Hippel-Lindau disease (VHL), Hereditary leiomyomatosis and renal cell cancer (HLRCC), Hereditary papillary renal carcinoma (HPRC), or Birt-Hogg-Dubé syndrome (BHD)
  • Patient has inflammation, atypia, or hyperplasia of the urothelium
  • Patient has a current or past history of urothelial cancer
  • Patient has undergone any prior radiation therapy to target lesion prior to surgery
  • Patient has received chemotherapy class drugs in the 5 years prior to surgery
  • Patient has had any transplants prior to surgery
  • Patient has confirmed or presumed lynch
• CASE BLOODS AND URINE:
  • Patient has known primary cancer outside of the kidney within the last 5 years prior to plasma and urine collection (not including basal cell or squamous cell skin cancers)
  • Patient has had surgery to completely or partially remove current target pathology
  • Patient has undergone any prior radiation therapy to target lesion prior to plasma and urine collection
  • Patient has received chemotherapy class drugs in the 5 years prior to plasma and urine collection
  • Patient has had any transplants prior to plasma and urine collection
  • Patient has confirmed or presumed lynch
  • Patient has von Hippel-Lindau disease (VHL), Hereditary leiomyomatosis and renal cell cancer (HLRCC), Hereditary papillary renal carcinoma (HPRC), or Birt-Hogg-Dubé syndrome (BHD)
• HEALTHY CONTROL BLOODS AND URINE:
  • Patient has known primary cancer outside of the urothelium within the last 5 years prior to plasma and urine collection (not including basal cell or squamous cell skin cancers)
  • Current target pathology is a recurrence
  • Patient has undergone prior radiation therapy in the 5 years prior to plasma and urine collection
  • Patient has received chemotherapy class drugs in the 5 years prior to plasma and urine collection
  • Patient has had any transplants prior to plasma and urine collection
  • Patient has von Hippel-Lindau disease (VHL), Hereditary leiomyomatosis and renal cell cancer (HLRCC), Hereditary papillary renal carcinoma (HPRC), or Birt-Hogg-Dube syndrome (BHD)
  • Patient has confirmed or presumed lynch
  • Gross urinary incontinence
  • Patient has undergone cystectomy

• CASE TISSUE:
  • Patient has a histological diagnosis of primary clear cell RCC, papillary cell RCC, clear cell papillary RCC, chromophobe RCC, oncocytoma, or urothelial cell carcinoma
  • Age \>= 18 years
• CASE BLOODS AND URINE:
  • Patient has a histological diagnosis of primary clear cell RCC, papillary cell RCC, chromophobe RCC, oncocytoma, or urothelial cell carcinoma
  • Age \>= 18 years
• HEALTHY CONTROL BLOODS AND URINE:
  • Patients has undergone negative hematuria workups (defined as negative abdominal imaging and negative cystoscopy
  • Age \>= 18 years